EPO / Erythropoietin

Erythropoietin (EPO) is a naturally occurring glycoprotein hormone produced mainly by the kidneys. Its central biological role is to signal the bone marrow to increase production of red blood cells, the cells that carry oxygen through the bloodstream.

Recombinant versions of the hormone (often referred to as epoetin alfa, epoetin beta, and related agents) are established, regulator-approved medicines. EPO is also widely known for its history of misuse in endurance sport, where raising red blood cell mass can increase oxygen delivery to muscle. That performance context is precisely why the substance is tightly controlled and why non-medical use carries significant danger.

EPO acts on erythroid progenitor cells in the bone marrow by binding the erythropoietin receptor. High-level themes include:

• Promoting the survival, proliferation, and maturation of red blood cell precursors

• Increasing the circulating red cell mass, which raises the blood's oxygen-carrying capacity and hematocrit

• Normally being regulated by tissue oxygen sensing, so that low oxygen levels prompt more EPO release

When red cell mass rises beyond physiological needs, blood becomes thicker and more viscous, which is central to understanding both the intended therapeutic effect and the serious risks of excess.

In approved clinical use, recombinant erythropoietin (epoetin) is prescribed to treat certain forms of anemia, most notably anemia associated with chronic kidney disease and anemia related to some chemotherapy regimens. It is used under medical supervision with monitoring of blood counts.

Outside of these supervised medical settings, EPO has been misused to boost endurance performance. This non-medical use is unsafe and prohibited. The gap between a carefully monitored clinical indication and unsupervised performance-oriented use is enormous, both legally and in terms of risk.

Sub-section S2.1 of the WADA Prohibited List is written around EPO and is unusually granular, because every attempt to evade the EPO test produced a new class that had to be listed:

• S2.1.1 — erythropoietin receptor agonists: epoetins, darbepoetins (dEPO), EPO-based constructs such as EPO-Fc and methoxy polyethylene glycol-epoetin beta (CERA), and EPO-mimetic agents such as peginesatide.
• S2.1.2 — HIF activating agents, e.g. cobalt, roxadustat (FG-4592), daprodustat, vadadustat, xenon.
• S2.1.3 — GATA inhibitors, e.g. K-11706.
• S2.1.4 — TGF-β signalling inhibitors, e.g. luspatercept, sotatercept.
• S2.1.5 — innate repair receptor agonists, e.g. asialo EPO and carbamylated EPO (CEPO) — the class that also captures non-erythropoietic EPO derivatives such as ARA-290.

EPO is a non-Specified Substance, so the default first-offence sanction is four years, and enforcement now runs on two independent tracks — direct detection in urine or serum, and indirect detection through the Athlete Biological Passport, which flags blood values inconsistent with an athlete's own longitudinal baseline. Recent USADA cases show both:

• Shadrack Biwott (track and field), four years. Direct detection: EPO was found in an out-of-competition urine sample collected 25 January 2024, and his ineligibility began 23 February 2024 (USADA announcement).

• Michael Brinegar (swimming), four years. Indirect detection: three samples collected between 20 July and 27 September 2022 produced blood values consistent with the use of erythropoietic stimulating agents. He contested the case and lost before the Court of Arbitration for Sport, with ineligibility running 21 June 2024 to 20 June 2028 (USADA announcement).

The Brinegar case is the important one to understand: no EPO was ever detected in his samples. The violation was established from the biomarker profile alone.

Even in approved therapeutic use, erythropoiesis-stimulating agents carry labeled warnings around cardiovascular events, thrombosis, and hypertension, which is why treatment is guided by careful blood count targets.

In unsupervised, non-medical use the dangers are amplified: there is no dosing oversight, no monitoring of hematocrit, and no management of the resulting blood viscosity. This is a substance where safety concerns are central rather than peripheral, and high-level summaries cannot substitute for clinical evaluation.

Conceptually, EPO is a large glycoprotein hormone whose activity depends on its glycosylation, and different recombinant agents vary in how long they persist in the body. Any legitimate use is a clinical decision made and monitored by a prescriber.

The key pharmacological idea for a general reader is that the therapeutic window is defined by blood counts, and that pushing red cell mass too high is where danger lies.

The erythropoiesis-stimulating agent class is a series of engineering attempts to make one hormone last longer in the blood:

• Epoetin alfa — Epogen (Amgen) and Procrit (Janssen), a 165-amino-acid glycoprotein of roughly 30,400 daltons produced in mammalian cells, with the identical amino-acid sequence to natural erythropoietin (Epogen prescribing information).

• Epoetin alfa-epbx — Retacrit (Pfizer), a biosimilar of epoetin alfa.
• Darbepoetin alfa — Aranesp (Amgen), a modified analogue approved for anemia of chronic kidney disease and chemotherapy-induced anemia, given at longer intervals than epoetin alfa.
• Methoxy polyethylene glycol-epoetin beta — Mircera (Vifor/Roche), an epoetin beta chemically linked to polyethylene glycol, which is what extends its persistence in circulation.

That progression is exactly why the WADA entry is written as a list of classes rather than a list of drugs: each longer-acting construct was a new molecule the existing test did not recognise.

Formulation detail matters clinically too. Epogen single-dose vials are preservative-free, while the multiple-dose vials contain benzyl alcohol, which is the reason the label restricts them in neonates — benzyl alcohol has been associated with gasping syndrome, hypotension, and cardiovascular collapse in preterm, low-birth-weight infants who cannot metabolise it.

The one combination that genuinely belongs in this section is iron. The Epogen label directs clinicians to evaluate iron status in every patient before and during treatment and to give supplemental iron when serum ferritin falls below 100 mcg/L or transferrin saturation below 20%, noting that most patients with CKD will need it during ESA therapy. Without iron there is nothing to build red cells from — a supportive requirement of the treatment, not a stacking strategy.

The evidence base for erythropoietin in approved indications, such as anemia of chronic kidney disease and certain chemotherapy-related anemias, is well-developed and shaped clinical guidelines. That same body of research also documented the cardiovascular and thrombotic risks that inform current dosing caution.

Research relevant to performance misuse is a separate story that focused heavily on detection methods rather than endorsing use. Because the risks are serious and well-characterized, claims that frame EPO as a safe performance aid are not supported by the evidence.

For deeper dives on this substance, see:

• EPO benefits and areas of interest
• EPO side effects and safety context
• EPO dosing concepts (educational)
• EPO research and evidence overview

What is EPO actually prescribed for? Four labeled indications, none of them athletic: anemia due to chronic kidney disease (on and off dialysis); anemia due to zidovudine in HIV infection where endogenous EPO is under 500 mUnits/mL; anemia from myelosuppressive chemotherapy where at least two more months of chemotherapy are planned; and reduction of allogeneic transfusion before elective non-cardiac, non-vascular surgery (Epogen prescribing information). The same label carries a "Limitations of Use" paragraph stating that Epogen has not been shown to improve quality of life, fatigue, or patient well-being — a striking sentence on a drug widely assumed to make people feel better.

Is EPO a peptide? It is a glycoprotein hormone rather than a synthetic peptide. The recombinant product is 165 amino acids with a molecular weight of roughly 30,400 daltons, and much of that mass is carbohydrate. The sugar chains are not decoration: glycosylation determines how long the hormone survives in circulation, which is why the different marketed agents behave differently despite acting on the same receptor.

Does EPO actually improve endurance performance? Less cleanly than its reputation suggests. In the best-controlled trial to date, 48 well trained male cyclists received a mean 6,000 IU per week of epoetin beta or placebo for eight weeks. Haemoglobin rose (9.6 vs 9.0 mmol/L), and laboratory maximal performance improved — peak power 351.6 W vs 341.2 W, VO₂max 60.1 vs 57.4 mL/min/kg. But submaximal performance was unchanged, and in a real 110 km road stage finishing with a competitive climb of Mont Ventoux, times were indistinguishable: 1 h 40 min 32 s versus 1 h 40 min 15 s (Heuberger et al., Lancet Haematol 2017). The honest reading is that EPO moves laboratory numbers reliably and race outcomes far less so.

Why is it dangerous in healthy athletes? Because the risk profile does not require a healthy baseline to bite. Every ESA carries a boxed warning that it increases the risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access, and tumour progression or recurrence — and the label states plainly that no trial has identified a haemoglobin target, dose, or dosing strategy that avoids these risks. In supervised care those risks are traded against transfusion avoidance and monitored weekly. Someone raising haematocrit for performance has no monitoring, no target, and no clinical reason to accept the trade.

How is EPO doping detected? Two independent routes. Direct detection identifies the exogenous molecule in urine or serum by separating glycoforms; indirect detection watches the athlete's own blood biomarkers over time through the Athlete Biological Passport (Salamin et al., Mol Cell Endocrinol 2018). The Brinegar case described above is the reason this matters: no EPO was found in his samples, and the violation rested entirely on the biomarker profile.

Isn't altitude training just natural EPO? The physiology overlaps — low tissue oxygen prompts the kidneys to release more erythropoietin — but the anti-doping rules do not track the mechanism, they track the intervention. Altitude exposure and hypoxic tents are not prohibited. Injecting a recombinant receptor agonist is, along with HIF activators, GATA inhibitors, TGF-β signalling inhibitors, and innate repair receptor agonists, all of which sit under S2.1 of the WADA Prohibited List.

Is there such a thing as a biosimilar EPO? Yes. Retacrit (epoetin alfa-epbx) was approved in 2018 as biosimilar to Epogen and Procrit, meaning it was licensed on data showing it is highly similar with no clinically meaningful differences from the reference product. Gray-market "EPO" sold outside a pharmacy is not a biosimilar in any regulatory sense; the term describes a specific FDA approval pathway, not a generic resemblance.